T C:API 'AL LLC7 EFTA00506132 Prediction BioSciences • One approved product (off-patent t-PA) to treat -1.7 M ischemic stroke episodes annually (US & EU only). • 30 - 50% of patients treated with t-PA will experience bleeding events, 6 - 1 1% are fatal. • First-to-market therapeutic-diagnostic com

1.5B. We are at 511.56. Reiterate Buy on valuation. We have increased our Sovaldi numbers in '14 by $700M to $5.7B We have taken up our numbers for US & EU Sovaldi over 2014 based on two trends 1) faster than expected launch in EU in a few countries (we previously assumed no sales in 1O in ELI) and 2) s

EFTA_R1_01138827 EFTA02295553 Prediction BioSciences • One approved product (off-patent t-PA) to treat H .7 M ischemic stroke episodes annually (US & EU only). • 30 - 50% of patients treated with t-PA will experience bleeding events, 6 - 1 1% are fatal. • First-to-market therapeutic-diagnostic co

1.5B.=We are at $11.58. Reiterate Buy on valuation. We have increased our Sovaldi numbers in '14 by $700M to $5.7B We have taken up our numbers for US & EU Sovaldi over 2014 based on two trends 1) faster than expected launch in EU in a few countries (we previously assumed no sales in 1Q in EU) and 2) s

11.SB.=We are at $11.58. Reiterate Buy on valuation. We have increased our Sovaldi numbers in '14 by $700M to $5.76 We have taken up our numbers for US & EU Sovaldi over 2014 based on two trends 1) faster than expected launch in EU in a few countries (we previously assumed no sales in 1Q in EU) and 2) s